Join us for Harnessing the Potential of Antibody Drug Conjugates (ADCs) in Oncology, on October 25 at Johnson & Johnson Innovation – JLABS @ Washington, DC. We’ll host industry thought [….]
Weekly Quick Hits (Greater Philly) – Week of May 29, 2023 By Mark TerryJune 2, 2023 Funding, Awards and Collaborations CHOP and More than 20 Institutions Create Open-Analysis Platform for [….]
Weekly Quick Hits (Greater Philly) – Week of May 8, 2023 By Mark TerryMay 12, 2023 Funding, Awards and Collaborations Interius Announces Manufacturing Partnership with WuXi Advanced Therapies Philadelphia-based Interius [….]
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 The approval is based on data from the pivotal CARTITUDE-1 study, which included patients who had received a median of six prior treatment regimens (range, 3-18), and had previously received a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.1 In December 2017, Janssen entered into an exclusive worldwide license and collaboration agreement with Legend Biotech USA, Inc. to develop and commercialize ciltacabtagene autoleucel.
Johns Hopkins Technology Ventures (JHTV) has had a significant impact on the Maryland life sciences ecosystem since its founding in 2014, assisting with hundreds of licensed therapeutics in development and backing nearly 200 startups that have collectively nearly $3 billion in venture capital funding, 30% of which has remained in the state.
Global COVID-19 cases have been spiking in Europe and the U.S. as the predicted second wave is hitting communities hard, applying new pressure on hospital capacity and forcing local and state governments to once again tighten restrictions.
Q&A With BeneVir Co-Founder and COO, Katherine Sacksteder, PhD – The Path to a Landmark Acquisition (Part 1) October 9, 2018 This has been a year marked by many notable biotech [….]
